Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. reports biotechnology developments centered on mRNA diagnostics, machine-learning analysis and non-invasive screening tests. Company news focuses on Revealia Breast, a cheek-swab breast cancer screening program that analyzes buccal cell mRNA biomarkers associated with inflammatory pathways, along with abstract publications tied to oncology research forums and journals.
Recurring updates also cover PCR validation work, provisional patent activity for cancer-screening algorithms, acquired intellectual property related to the mRNA Neuro Panel and Serotonin Assay, and governance changes as the company advances from research and diagnostic development toward healthcare solutions.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) has announced significant corporate initiatives as it prepares to launch Revealia™, its innovative cancer screening test, in 2024. The company plans to change its name to Revealia™, Inc. and apply for OTCQB listing, with aspirations for higher listings like NASDAQ or CBOE in the future. Revealia™ is positioned as the world's most convenient cancer screening test, utilizing a simple mail-order noninvasive cheek swab.
The company has collected over 3000 mRNA samples from multiple medical clinics across the US and employs proprietary machine learning AI technology for continuous statistical updates. CEO Marvin S. Hausman, MD, states that Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with cancer presence.
Ludwig Enterprises has filed a provisional patent for an mRNA genetic screening technique targeting breast, colon, and bladder cancers. The innovation focuses on identifying and differentiating cancers and assessing treatment effectiveness through mRNA biomarkers. These biomarkers are dynamic genetic signals that can revolutionize cancer diagnostics. The company is leveraging machine learning AI to continuously update statistical models using patient data from over 40 clinics in the U.S. CEO Marvin S. Hausman highlighted the significance of the breakthrough in tapping into the billion-dollar cancer diagnostic market. Cheek cell samples, collected noninvasively, are analyzed to detect these mRNA biomarkers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.